Evidence map›Paper›PMID 40103228›Full record

ArticleNucleic acids research2025

Enhanced or reversible RNA N6-methyladenosine editing by red/far-red light induction.

Heng Tang, Shaoqin Han, Yang Jie, Xin Jiang, Yi Zhang, Junran Peng, Fang Wang, Xiang Li, Xiang Zhou, Wei Jiang and 1 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. The Role of NMedComm · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Heng TangDepartment of Otorhinolaryngology-Head and Neck Surgery, Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430072, China.
Shaoqin HanCollege of Chemistry and Molecular Sciences, Key Laboratory of Biomedical Polymers of Ministry of Education, Hubei Province Key Laboratory of Allergy and Immunology, Wuhan University, Wuhan 430072, P.R. China.
Yang JieDepartment of Biological Repositories, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China.
Xin JiangCollege of Chemistry and Molecular Sciences, Key Laboratory of Biomedical Polymers of Ministry of Education, Hubei Province Key Laboratory of Allergy and Immunology, Wuhan University, Wuhan 430072, P.R. China.
Yi ZhangDepartment of Otorhinolaryngology-Head and Neck Surgery, Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430072, China.
Junran PengCollege of Chemistry and Molecular Sciences, Key Laboratory of Biomedical Polymers of Ministry of Education, Hubei Province Key Laboratory of Allergy and Immunology, Wuhan University, Wuhan 430072, P.R. China.
Fang WangWuhan University School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China.
Xiang LiDepartment of Otorhinolaryngology-Head and Neck Surgery, Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430072, China.
Xiang ZhouCollege of Chemistry and Molecular Sciences, Key Laboratory of Biomedical Polymers of Ministry of Education, Hubei Province Key Laboratory of Allergy and Immunology, Wuhan University, Wuhan 430072, P.R. China.ORCID 0000-0002-1829-9368
Wei JiangDepartment of Biological Repositories, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China.ORCID 0000-0002-6463-7356
Xiaocheng WengDepartment of Otorhinolaryngology-Head and Neck Surgery, Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430072, China.ORCID 0000-0002-0605-8495

Funding

Fundamental Research Funds for the Central Universities 2042023kfyq05Ministry of Science and Technology 2023YFC3402200National Natural Science Foundation of China 92253202
6 · The paper itself

Abstract

The RNA N6-methyladenosine (m6A) modification is a critical regulator of various biological processes, but precise and dynamic control of m6A remains a challenge. In this work, we present a red/far-red light-inducible m6A editing system that enables efficient and reversible modulation of m6A levels with minimal off-target effects. By engineering the CRISPR dCas13 protein and sgRNA with two pairs of light-inducible heterodimerizing proteins, ΔphyA/FHY1 and Bphp1/PspR2, we achieved targeted recruitment of m6A effectors. This system significantly enhances m6A writing efficiency and allows dynamic regulation of m6A deposition and removal on specific transcripts, such as SOX2 and ACTB. Notably, reversible m6A editing was achieved through cyclic modulation at a single target site, demonstrating the ability to influence mRNA expression and modulate the differentiation state of human embryonic stem cells. This optogenetic platform offers a precise, versatile tool for cyclic and reversible m6A regulation, with broad implications for understanding RNA biology and its potential applications in research and medicine.

Indexed as

AdenosineGene EditingLightRNA EditingCell DifferentiationCRISPR-Cas SystemsHEK293 CellsHuman Embryonic Stem CellsHumansOptogeneticsRed LightRNA, Guide, CRISPR-Cas SystemsRNA, MessengerSOXB1 Transcription FactorsAdenosineN-methyladenosineRNA, Guide, CRISPR-Cas SystemsRNA, MessengerSOX2 protein, humanSOXB1 Transcription Factors

Identifiers

PMID40103228
PMCPMC11915503

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.